-3%
Otegal is indicated for the reduction of recurrent vulvovaginal candidiasis (RVVC) episodes in adult females who are not of reproductive potential. While fungal culture results can guide therapy, treatment may be initiated prior to receiving laboratory confirmation. Adjust treatment based on culture findings when available.
- Pediatric: Not recommended due to contraindication in reproductive-aged females.
- Geriatric: Insufficient data; caution advised.
- Renal Impairment: No dose adjustment needed in mild to moderate cases.
- Hepatic Impairment: No adjustment necessary for mild liver dysfunction (Child-Pugh A).
Oteseconazole is a novel antifungal agent from the azole class. It selectively inhibits the fungal enzyme 14α-demethylase (CYP51)—crucial for ergosterol biosynthesis, an essential component of the fungal cell membrane. Disruption of this process compromises fungal cell integrity and viability. The drug’s tetrazole moiety gives it high specificity for fungal enzymes while minimizing interaction with human cytochrome P450 enzymes.